Run your EDC and eCOA solutions on the exact same database. See toxicity and QoL data the moment a patient submits it, with no reconciliation lag and no integration tax between two vendors. Builds are scoped with managed Professional Services so amendments and go-live stay on a predictable timeline.
In oncology, patient safety and dose modifications depend on real-time data. But legacy systems force you to capture objective clinical data in one system and subjective quality-of-life data in another. That integration tax shows up as real operational costs every day.
Reconciliation delays between your EDC and eCOA hold up investigators before they can act on toxicity data. Critical dose modification decisions get delayed while teams wait for a system sync.
Capturing clinical data in one system and patient-reported data in another means site staff manage two logins, two training programmes, and two support channels. The overhead lands on the people running the study every day.
Oncology protocols change. Basket trials add cohorts, adaptive designs modify dosing arms, and regulatory feedback requires CRF updates mid-study. Legacy enterprise EDC systems take weeks to revalidate after a protocol change.
Data discrepancies between systems go undetected until lock, when they are expensive to fix. Investigators wait on a scheduled sync to see QoL and adverse event data, so decisions for the next cycle slip.
With Castor, EDC and eCOA run on the exact same database. No swivel-chair data management, no reconciliation lag, and one unified view of every patient, updated the moment data is submitted.
When an oncology patient logs a Grade 3 toxicity event at home, investigators should not have to wait for a system sync to act on it. Castor ePRO feeds directly into the eCRF, the same database, not a connected one. Investigators see QoL and adverse event data the moment it is submitted, and dose modification decisions for the next cycle can be made immediately.
Oncology protocols change. Basket trials add cohorts. Adaptive designs modify dosing arms. Regulatory feedback requires CRF updates mid-study. Legacy enterprise EDC systems take weeks to revalidate after a protocol change. Castor mid-study amendments deploy without downtime, without a full rebuild, and without waiting in a vendor queue.
Castor scopes each study build with managed Professional Services. Low-to-medium complexity studies typically move from kickoff (KOM) to user acceptance testing (UAT) in 4 to 8 weeks, and high-complexity studies in 8 to 12 weeks. The managed, scoped approach keeps the build on a predictable timeline rather than waiting in a vendor queue.
Oncology patients carry immense physical and emotional burdens. Their clinical trial software should not add to it. Castor’s patient app is designed for ease, not for clinical data managers who assume patients will tolerate difficult tools.
BYOD-friendly, so patients use their own smartphone with no provisioned device to manage. A 24/7 multilingual patient helpdesk supports 15 to 20 languages, and the interface is accessible with large text, simplified navigation, and audio prompts.
EHR/EMR data feeds via Castor Catalyst reduce manual entry burden for sites managing high patient volumes. With Castor Catalyst, AI-assisted extraction with human review cuts record review from around 5 hours to roughly 20 minutes per record. Mid-study amendments include patient re-consenting workflows, so amended protocols reach enrolled patients without a separate eConsent process. For oncology teams building real-world evidence programmes alongside their interventional trials, Catalyst bridges interventional data capture and evidence suitable for regulatory submission.
We will build a real oncology study in front of you, including mid-study amendment, ePRO setup, and toxicity reporting. It takes 15 minutes.
From agile biotech interventional trials to massive global registries, Castor handles the full spectrum of modern oncology data management.
Over 1.62 million data points captured for over 21,000 patients at Erasmus MC, demonstrating Castor’s ability to scale to large-volume observational oncology programmes without custom infrastructure.
Nearly 5,000 patients captured at a single centre (Radboud UMC), proving Castor can handle high-volume single-site oncology registries with complex longitudinal data requirements.
Oncobiomix, an oncology biomarker-validation study led by Dr. Michael Liss (urologic oncology), ran on Castor with 95%+ ePRO compliance and around $100,000 in savings, showing how a unified EDC and ePRO build keeps patient-reported data complete while controlling study cost.
A factual overview for buyers evaluating Castor against legacy enterprise platforms. All claims are based on publicly available information as of April 2026. See the full Castor vs. Medidata comparison.
| Feature | Castor | Medidata Rave EDC | Veeva Vault EDC | Clario / IQVIA eCOA |
|---|---|---|---|---|
| EDC and eCOA in one system | ✓ Native — same database | ✗ Requires separate eCOA vendor | ✗ Requires separate eCOA vendor | ▬ eCOA only, needs EDC |
| Deployment time† | 4 to 8 weeks (low-to-medium complexity), 8 to 12 weeks (high complexity) | Varies by build type | Varies by build type | Varies. Add to EDC timeline |
| Mid-study amendments | Zero downtime | Weeks, full revalidation required | Moderate, depends on configuration | eCOA-side only |
| Patient ePRO app | Consumer-grade BYOD app | Available as separate module | Limited native ePRO | Core strength, device or BYOD |
| ePRO compliance rate | 95%+ in the Oncobiomix oncology study | Not published | Not published | High,core competency |
| Regulatory compliance | 21 CFR Part 11, ICH E6(R3), GDPR, HIPAA | 21 CFR Part 11, GDPR | 21 CFR Part 11, GDPR | 21 CFR Part 11, GDPR |
| Best fit for | Biotech and mid-pharma teams running fast-moving oncology trials | Large pharma, NCI trials, enterprise scale | Enterprise pharma, Veeva ecosystem users | Trials requiring specialist standalone eCOA |
† Deployment time varies by build complexity and vendor configuration. Legacy industry builds average 10 to 14 weeks.
All competitor information is based on publicly available data as of April 2026. Castor does not claim to be superior in all contexts. Medidata Rave has a longer regulatory submission track record with FDA, EMA, and PMDA that is material for large pharma organisations standardised on its workflows. Verify current capabilities directly with each vendor.
Every oncology study on Castor operates within a fully validated, regulation-ready environment. No separate compliance implementation required.
| Standard | What it means for your oncology trial |
|---|---|
| FDA 21 CFR Part 11 | Full electronic records and signature compliance, required for FDA submission of oncology trial data |
| ICH E6(R3) GCP | Good Clinical Practice aligned, all data handling meets international GCP standards for oncology research |
| GDPR and HIPAA | Patient data handling compliant across EU and US jurisdictions, required for global oncology trials with sites in multiple regions |
| FDA PRO Guidance (2009) | Patient-reported outcome measures collected via Castor ePRO meet FDA guidance for oncology label claims |
| EORTC and ASCO PRO standards | ePRO instruments configured in line with EORTC and ASCO recommendations for oncology QoL endpoint collection in clinical trials |
| ISO 27001 | Information security management system certified, data security audited to international standard |
Recognized as a Major Contender in Everest Group’s Life Sciences eCOA Products PEAK Matrix® Assessment 2025.
Rated strongly for customer loyalty in ISR’s 2025 eCOA/ePRO Benchmarking.
Oncology research runs against tight constraints. Patient populations are often small, dose-modification windows are short, and quality-of-life endpoints matter as much as the objective clinical readout. Investigators need toxicity and QoL data while there is still time to act on it for the next cycle, not after a scheduled system sync. Oncology clinical trial software is what manages those data collection, patient reporting, and regulatory documentation workflows. It typically combines an electronic data capture system (EDC) for objective clinical measurements with electronic patient-reported outcomes (ePRO) for symptom assessments, QoL scores, and toxicity monitoring. When those systems are separate, teams face reconciliation delays and data discrepancies that slow dose-modification decisions. Castor provides a unified platform where both data streams share the same database, removing the synchronization overhead of a two-vendor architecture.
EDC and ePRO share the same database, so there is no synchronization overhead and no reconciliation step between two vendors.
586 oncology studies are currently active on Castor, spanning Phase I through Phase III interventional trials, adaptive basket trials, and large observational registries.
Active oncology studies run across dozens of countries, with 175,000+ patients enrolled. Castor offers local data hosting in regions including Australia, helping global sponsors meet data-residency requirements.
Castor ePRO is built natively into the EDC, not connected via an API. When an oncology patient logs a Grade 3 toxicity event at home or completes a QoL assessment (EORTC QLQ-C30, FACT), that data appears instantly in the eCRF. Investigators can review it in real time and make dose modification decisions for the next treatment cycle without waiting for a system sync.
Castor scopes each study build with managed Professional Services. Low-to-medium complexity studies typically move from kickoff (KOM) to user acceptance testing (UAT) in 4 to 8 weeks. High-complexity studies take 8 to 12 weeks. For biotech teams racing to first patient in, this managed, scoped approach keeps the build on a predictable timeline rather than waiting in a vendor queue.
Yes. Castor provides 190+ out-of-the-box oncology PRO instruments including EORTC QLQ-C30 and FACT, enabling QoL data capture natively within the EDC platform without a separate eCOA system.
Yes. Castor provides 190+ out-of-the-box oncology PRO instruments including EORTC QLQ-C30 and FACT, enabling QoL data capture natively within the EDC platform without a separate eCOA system.* Sponsor licensing is required for certain proprietary PRO instruments.
Yes. Castor is fully compliant with FDA 21 CFR Part 11 (electronic records and signatures), aligned with ICH E6(R3) Good Clinical Practice standards, and meets GDPR and HIPAA data handling requirements across EU and US jurisdictions.
Castor supports the full range of oncology study types: Phase I, II, and III interventional trials, adaptive and basket trials, observational studies, and post-approval registries. Active oncology studies include complex biotech interventional trials, large observational registries capturing millions of data points, and multi-site global studies. Real-world evidence programmes and oncology registries are also supported natively.